Applications of Radionuclide Therapy Dosimetry- Worked Examples

Yuni K Dewaraja

Department of Radiology
University of Michigan

Introduction to Radionuclide Therapy Dosimetry, AAPM Annual Meeting CE Session, San Antonio, Juy 2019

Disclosures

- Yuni Dewaraja is a consultant for MIM Software, Inc.

Internal Therapy Dosimetry: Main Steps

- Image Acquisition – usually at multi time points
  - 2D Planar, 3D SPECT or PET, Hybrid Planar/SPECT
- Image Reconstruction
  - Iterative with corrections
- Segmentation (on functional or anatomical images)
- Quantification (conversion of reconstructed counts to activity)
  - Calibration factor/camera sensitivity (cps per unit activity)
  - Partial volume Ccrrection
- Time – activity fitting, time integrated activity
- Absorbed dose (AD) estimation
  - Time-integrated activity to AD or activity maps to dose-maps

Patient AD calculation in 2 therapies will be presented

1. ^{90}Y microsphere radioembolization (RE) in hepatic malignancies
   - Current treatment: minimally patient specific
   - Motivation for dosimetry based treatment approach: despite promising response rate survival is poor
   - Examples: Pre-therapy for planning, post for verification
2. ^{177}Lu DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumor (NET)
   - Current treatment: fixed activity/cycles (4 x 7.4 GBq)
   - Motivation for dosimetry based treatment approach: despite promising progression free survival, poor complete response
   - Example: During therapy (after first cycle) dosimetry

Patient specific dosimetry in Y-90 radioembolization

- Quantitative imaging for dosimetry is complex
  - Y-90 'pure' β emitter
    - SPECT via bremsstrahlung photons
    - PET via low yield positron
  - Need imaging surrogate for planning
    - Differences between MAA particles vs. microspheres



But

- Practical to implement clinical dosimetry
  - Microspheres do not re-distribute
    - Need only a single imaging time point. Liver relative calibration
  - No γ-rays and short β range relative to resolution
    - Voxel-level dosimetry assuming local energy deposition

Y-90 radioembolization dosimetry

$$MIRD\ schema\ for\ AD:\quad \bar{D}(r_T) = \sum_{r_S} \tilde{A}(r_S) S(r_T \leftarrow r_S)$$

AD to target per transformation in source

$\tilde{A}(r_S) = A(r_S, 0) \int_0^\infty e^{-\lambda t} = A(r_S, 0)/\lambda$
Assuming physical decay only

S = Beta energy per decay/mass = 49.38 J/GBq
Assuming all energy abs. in mass

$$\bar{D}_{VOI}(Gy) = 49.38\ \mathrm{J/GBq} \cdot \frac{A_{VOI,0}[\mathrm{GBq}]}{m\ [\mathrm{kg}]}$$

$$A_{VOI,0} = \frac{C_{VOI,0}\ (cps)}{CF\ (cps/MBq)} = C_{VOI,0} \frac{A_{liv,0}}{C_{liv,0}} = C_{VOI,0} \frac{A_{admin} * (1-LSF)}{C_{liv,0}}$$

$= \frac{C_{liv}}{A_{liv}}$
Liver relative calibration

$A_{liv,0} = A_{admin} *$ (1-LSF)
Assuming all admin. activity is in liver and lung

Dezarn et al. Recommendations of the AAPM ...Med Phys , 38(8) 2011

Partial volume correction

- Even with resolution modeling in iterative reconstruction, counts are not fully recovered in 'small' objects
  - Need PVC for quantification
  - Most practical is to use recovery coefficients (RC)
  - Phantom under similar conditions as in patient study
  - RC vs. volume curve

$$A_{\mathrm{VOI}}(corrected) = \frac{A_{\mathrm{VOI}}}{RC(v)}$$







Dewaraja et al, MIRD 23 J Nucl Med 2012

Y-90 radioembolization example: study details

- Patient with metastatic adrenal cancer treated with 1.3 GBq Y-90 glass microspheres (Theraspheres) to the right lobe (700 cc)
- Pre-treatment (4 weeks prior) Tc-99m MAA (185 GBq)
  - Imaging ~ 2h post-admin
  - Planar: to determine lung shunt (2%)
  - SPECT/CT: to evaluate extra hepatic deposition
    - 4 iterations 8 subsets of OSEM with post-filter
- Post-therapy Y-90 time-of-flight PET/CT imaging as part of a research study
  - Imaging at ~ 2 h post RE (before discharge)
    - 1 iteration 21 subsets of OSEM with post-filter

Y-90 RE patient example: pre- and post-imaging

- Diagnostic quality MR used to segment
  - Lesions (> 2 mL) manually by radiologist
  - Liver by technologist using semi-automatic software
  - Non-tumoral liver = liver minus lesions
- Applied to co-registered SPECT/CT and PET/CT
  - Some fine tuning of contours to account for mis-registration



Y-90 RE patient example: AD estimation





Tc-99m MAA: $A_{tum} = C_{tum}\frac{A_{liver}}{c_{liv}}$

$= 62662504 * \frac{1.3}{594511232} = 137$ MBq

$=137/0.7 = 202$ MBq (with PVC)

$\bar{D}(Gy) = 49.38 \cdot \frac{202\ MBq}{11cc*1.03\ g/cc}$ = 880 Gy

Y-90 PET can use act. directly from image:

$A_{tum} = 110\ MBq$

$=110/0.6 = 170$ MBq (with PVC)

$\bar{D}(Gy) = 49.38 \cdot \frac{170\ MBq}{11cc*1.03\ g/cc}$ = 742 Gy

		Predicted (from Tc-99m)		Delivered (from Y90-PET)	
	Volume (cc)	Act. (MBq)	Dose (Gy)	Act. (MBq)	Dose (Gy)
Lesion 1	11	202	880	170	742
NT Liver	1140	1060	45	902	38

Y-90 RE patient dosimetry example: uncertainty

- Law of propagation of uncertainties
  - *Joint Committee for Guides in Metrology. Evaluation of measurement data - Guide to the expression of uncertainty in measurement (GUM). BIPM 2008*
- Application to internal dosimetry





$A_{VOI} = \frac{C_{VOI}}{R_{VOI} * CF}$

$\frac{u(A_{VOI})}{A_{VOI}} = \sqrt{\left(\frac{u(CF)}{CF}\right)^2 + \left(\frac{u(R_{VOI})}{R_{VOI}}\right)^2 + \left(\frac{u(C_{VOI})}{C_{VOI}}\right)^2 - 2\frac{u(R_{VOI},C_{VOI})}{R_{VOI}C_{VOI}}}$

$D_{VOI} = k * \frac{A_{VOI}}{M_{VOI}}$

$\frac{u(D_{VOI})}{D_{VOI}} = \sqrt{\left(\frac{u(A_{VOI})}{A_{VOI}}\right)^2 + \left(\frac{u(M_{VOI})}{M_{VOI}}\right)^2 - 2\frac{u(A_{VOI},M_{VOI})}{A_{VOI}M_{VOI}}}$

	Volume (mL)	RC (Y-90 PET)	AD (Gy)	STD Uncert.
Lesion	11	0.6	742	10%
Normal liver	1140	0.9	38	5%

SPECT/CT or PET/CT based patient specific 3D dosimetry



Y90 RE patient example: 3D Monte Carlo dosimetry





	Volume (cc)	Mean Dose (Gy)
Lesion 1	11	735
Lesion 4	5	779
Non-tumor liver	1140	38

** Wilderman and Dewaraja. IEEE Trans Nucl Sci 2007;54:146.*

Y-90 RE dosimetry: Do we need Monte Carlo?

- Comparison of estimates from MC with estimates from local energy deposition assumption

	DPM* Monte Carlo Absorbed Dose (Gy)	Difference compared with Local Energy Deposition
8 mL sphere	191	2.5%
16 mL sphere	246	1.6%
29 mL ovoid	249	0.8%
Healthy liver	59	-1.6%
L Lung	4.5	-144% (-10%)
R Lung	4.8	-144% (-6%)

with density correction



Y90 PET-CT study at Univ Mich: Dose – outcome

- TCP models showed a strong association between dose metrics and the probability of response (for AD, AUC = 0.87 sensitivity = 0.75 and specificity = 0.83)

	Mean [Range] Responding* lesions	Mean [Range] Nonresponding* lesions	p-value
AD (Gy)	559 [90 - 1271]	183 [2 - 574]	<0.0001
BED (Gy)	1129 [102 - 4337]	255 [2 - 809]	<0.0001



- No statistically significant correlation between non-tumoral liver AD and liver toxicity

Dewaraja et al. JNM 2019 (in press)

^{177}Lu DOTATATE PRRT of NETs: Benefit of individualized treatment

- Studies where number of cycles were adapted based on SPECT/CT based dosimetry after each cycle
  - *Sandstrom et al, ACTA ONCOL. 2018*
    - BED < 38 Gy to kidney and AD < 2 Gy to marrow
  - Sundlov et al, EJNMMI 2017
    - BED < 27 Gy to kidney
- # of cycles increased in most patients without reaching toxicity 'limits'





Lu-177 PRRT dosimetry: quantitative SPECT/CT imaging

- Image acquisition: ME collimator, typically using 208 keV peak (10%). Also 113 keV peak (6%) available
- Quantification:
  - Can use OS-EM reconstruction with TEW scatter correction
  - Planar point source or SPECT phantom based calibration
    - Some new systems have 'in-built' Lu-177 calibration
      - Image in units of Bq/mL
  - RCs still needed



Ljungberg et al, MIRD 26, JNM 2017.

SPECT camera calibration procedure

Conventional 'Manual' calibration



Approach 1

Approach 2

Planar sensitivity

$S = C_{ref}/A_{ref}$ $(cps\ per\ MBq)$

SPECT with phantom

'Built in' with monthly checks (xSPECT)

NIST traceable Se-75 source attached to integrated source holder in FOV

Bergeron & Cessna. Nuc Med Comm. 39: 500 - 504

RCs for Lu-177: demonstrating impact of object shape



Lu-177 PRRT patient dosimetry example: SPECT/CT

- Quantitative SPECT/CT
  - day 0,1,4,5 after cycle 1
  - 80 mAs, 130 kVp CT on day 0, day1-5, 15 mAs CT for AC only
  - SPECT image directly in Bq/mL
- Segmented on day 0 CT
  - lesions > 4 mL by radiologist kidney by technologist
  - Co-register time points
- RCs for PVC
- Mono- or bi-exponential fit



	Vol mL	RC	Activity (STD) MBq			
			Day 0	Day 4	Day 5	Day 7
Lesion	111	0.94	168 ±8	108 ±5	85 ±4	71 ±3
R kidney	261	0.86	100 ±6	23±1	16 ±1	10 ±1
L kidney	277	0.86	108 ±6	27 ±2	18 ±1	11 ±1

Lu-177 PRRT patient dosimetry example: time-activity





$$R\ Kidney \quad \tilde{A} = 100 * \int_0^\infty e^{-0.013\pi t} = \frac{100}{0.0138} = 7225\ \text{MBq} - \text{h}$$

$$L\ Kidney \quad \tilde{A} = 110 * \int_0^\infty e^{-0.013\pi t} = \frac{110}{0.0138} = 7964\ \text{MBq} - \text{h}$$

Lesion $\tilde{A} = 184 * \int_0^\infty (e^{-0.0057t} - e^{-0.6027t})$
= 184* (1/0.0057 - 1/0.6027)
= 32111 MBq-h

Lu-177 PRRT example: kidney absorbed dose

MIRD schema for AD : $\bar{D}(r_T) = \sum_{r_S} \tilde{A}(r_S) S(r_T \leftarrow r_S)$ — AD to target per transformation in source

$$\bar{D}(r_{kid}) = \tilde{A}(r_{kid}) S(r_{kid} \leftarrow r_{kid}) + \tilde{A}(r_{rb}) S(r_{kid} \leftarrow r_{rb})$$

$5.70 \cdot 10^{-5} \frac{\text{mGy}}{\text{MBq} \cdot \text{s}}$

$$= S(r_{kid} \leftarrow wb) \cdot \frac{m(wb)}{m(rb)} - S(r_{kid} \leftarrow r_{kid}) \cdot \frac{m(r_{kid})}{m(rb)}$$

$$= 3.53 \cdot 10^{-7} \cdot \frac{7300}{(7300-422)} - 5.70 \cdot 10^{-5} \cdot \frac{422}{(7300-422)} = 2.36 \cdot 10^{-8} \frac{\text{mGy}}{\text{MBq} \cdot \text{s}}$$

$$\bar{D}(r_{kid}) = (7225 + 7964) * 3600\ MBq.s\ * 5.70 \cdot 10^{-5}\ \frac{\text{mGy}}{\text{MBq} \cdot \text{s}}$$
$$+ 205686 * 3600\ MBq.s\ * 2.36 \cdot 10^{-8}\ \frac{\text{mGy}}{\text{MBq} \cdot \text{s}} = 3.1\ \text{Gy}$$

With mass scaling, $S(r_{kid} \leftarrow r_{kid}) = S(r_{kid} \leftarrow r_{kid}) * \frac{m(ref)}{m(pat)}$

then $\bar{D}(r_{kid}) = 2.4\ Gy$

MIRD Primer for Absorbed Dose Calculation 1991

Lu-177 PRRT example: lesion absorbed dose

- OLINDA unit density sphere model (self-dose only) for 111 mL lesion:
  S = 2.2 x 10^{-4} mGy/MBq.s
- Tumor AD

$$\bar{D}(r_{tum}) = \tilde{A}(r_{tum}) S(r_{tum} \leftarrow r_{tum})$$

= *32111* 3600 MBq.s * 2.2x 10^{-4} mGy/MBq.s * 0.001*

= *25 Gy*



Stabin MG et al. OLINDA/EXM: the second-generation personal computer software … J Nucl Med. 2005 Jun;46(6):1023-7

Lu-177 PRRT patient example:3D Monte Carlo dosimetry

DPM MC Voxel-level Dosimetry



MC based mean AD
Tumor: 24 Gy
R Kidney: 2.4 Gy
L Kidney: 2.4 Gy

Lesion dose map with Iso dose contours(Gy)

Thank You
To patients who volunteered for the presented clinical studies.

To collaborators/students Jeff Fessler PhD, Pete Roberson PhD, Scott Wilderman PhD, Mark Kaminski MD, Anca Avram MD, Kyle Cuneo MD, Bill Majdalany MD, Dawn Owen, MD, Ravi Kaza MD, Ravi Srinivasa MD, Justin Mikell PhD, Ka Kit Wong MD, Kirk Frey MD, Issam El Naqa, PhD, Hongki Lim, MSc, Se Young Chun, PhD

Funding from NIH(NIBIB) grants R01EB001994 and R01EB022075 is acknowledged

yuni@umich.edu

Questions

1. Which of the following is the major contributor to self absorbed dose in therapies involving Lu-177 or Y-90

a. Bremsstrahlung photons
b. Gamma-rays
c. Beta-particles
d. Both gamma-rays and beta particles contribute equally

Reference: Sandström M, Garske-Román U, Johansson S, Granberg D, Sundin A, Freedman N. Kidney dosimetry during (177)Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. Acta Oncol. 2018 Apr;57(4):516-521.

Questions

2. Source region time-integrated activity for post-therapy imaging based absorbed dose estimation in Y-90 microsphere radioembolization typically

a. requires Y-90 imaging at multiple time points
b. requires Y-90 imaging at a single time point
c. can be obtained by PET imaging only
d. cannot be determined as Y-90 has no associated gamma-rays

Reference: Elschot M, Vermolen BJ, Lam MG, de Keizer B, van den Bosch MA, de Jong HW.
Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One. 2013;8(2):e55742.